Home
Live Updates
Calliditas Therapeutics: In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYOs Mode of Action : comparemela.com
Calliditas Therapeutics: In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
STOCKHOLM, May 16, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day
Related Keywords
Stockholm ,
Sweden ,
United States ,
Leicester ,
United Kingdom ,
American ,
Jonathan Barratt ,
Garethj Thomas ,
Gareth Thomas ,
Phd University Hospital Southampton ,
Renal Research Group ,
Life Sciences ,
University Of Leicester ,
American Society Of Nephrology Kidney Health Initiative ,
Iga Nephropathy Network ,
University Of Southampton ,
Rare Disease Group ,
Inderes Event Studio ,
University Hospital Southampton ,
Experimental Pathology ,
United Kingdom National Registry ,
Rare Kidney Diseases ,
In Ternational Iga Nephropathy ,
Chief Investigator ,
American Society ,
Nephrology Kidney Health Initiative ,
Identifying Surrogate Endpoints ,
Clinical Trials ,
Iga Nephropathy Work ,
Ihr Portfolio ,
Calliditas ,
Herapeutics ,
Person ,
Irtual ,
Anti ,
Fibrotic ,
Effects ,
Setanaxib ,
Tarpeyo ,
Mode ,
Action ,
comparemela.com © 2020. All Rights Reserved.